WALTHAM, Mass.--(BUSINESS WIRE)--March 3, 2005--Interleukin Genetics, Inc. (OTCBB: ILGN) reported today that it has signed two new Research Agreements with Access Business Group LLC, a subsidiary of Alticor Inc. The Company also reported that it has modified its Stock Purchase and Distribution Agreements with other affiliates of Alticor.
Under one of the new research agreements Interleukin will conduct research to develop risk assessment tests for the Asian market; under the other ILGN will undertake exploratory research to identify new product opportunities. With the execution of these two agreements, Interleukin is eligible to receive up to $5.0 Million in additional research funding over a period of 24 months beginning on April 1, 2005.